Posted: January 28, 2008

Arrowhead Announces the Appointment of Dr. Mauro Ferrari to Its New Board of Advisors

(Nanowerk News) Arrowhead Research Corporation announced today the appointment of Dr. Mauro Ferrari to its newly established Board of Scientific Strategy. He is one of the most well-known experts in leveraging nanotechnology to treat and diagnose cancer. Dr. Ferrari will serve as a Director of Scientific Strategy and will be integral in building out the new advisory board and guiding Arrowhead’s operations and strategic plan.
“We are truly honored to have Dr. Ferrari as part of our team,” said Chris Anzalone, Arrowhead’s CEO. “He is one of the most innovative thinkers in nanotechnology and brings a uniquely varied approach to science that spans silicon engineering and cancer biology.”
The Advisory Board, to be comprised of some of the world’s most prolific pioneers in nanotechnology and medicine, will develop a scientific roadmap to guide Arrowhead’s CEO in establishing Arrowhead as the preeminent outlet for commercializing and monetizing revolutionary advances in the field. It will provide broad scientific direction for the Company as well as very specific recommendations with respect to technologies that should serve as the basis for new companies, technologies that could augment the scientific and market positions of existing subsidiaries, and recruiting world class personnel for Arrowhead and its subsidiaries. In addition, these thought leaders have deep relationships within academia and industry, and will be critically involved in establishing partnerships for Arrowhead and its subsidiaries.
“With its exceptional portfolio of companies and platform nanotechnologies, Arrowhead is in a unique position to develop and bring to the clinic new approaches and products that will revolutionize healthcare,” said Dr. Ferrari.
Dr. Mauro Ferrari serves in a number of academic roles, including President of the Alliance for NanoHealth in Houston, TX; Professor & Director of the Center for NanoMedicine, Brown Foundation Institute of Molecular Medicine; Chairman of the Department of Biomedical Engineering at the University of Texas Health Science Center at Houston; Professor of Experimental Therapeutics at the University of Texas M.D. Anderson Cancer Center; and Professor of Bioengineering at Rice University. Dr. Ferrari is a founder of biomedical nano/micro-technology in biomedical applications, with more than 160 peer-reviewed journal articles, six books, more than 20 issued patents and about 30 more pending in the US and internationally. His career research and development portfolio totals over $50 million. Dr. Ferrari served as Special Expert on Nanotechnology at the National Cancer Institute in 2003-2005, providing leadership into the establishment of the NCI’s Alliance for Nanotechnology. Dr. Ferrari received a Ph.D. in Mechanical Engineering from U.C. Berkeley, where he also served as Professor of Materials Science and Engineering.
About Arrowhead Research Corporation
Arrowhead Research Corporation ( (NASDAQ:ARWR) is a leading nanotechnology company commercializing new technologies in the areas of life sciences, electronics and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has five subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, fullerene anti-oxidants, carbon-based electronics and compound semiconductor materials.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our clinical studies, our ability to successfully develop and manufacture products, rapid technological change in our industry, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, and other SEC filings discuss these and other important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
Source: Arrowhead Research Corporation
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: